News|Articles|August 24, 2023

FDA Warns Public to Not Purchase or Use Specific Eye Drop Brands

The federal agency says everyone should immediately stop using Dr. Berne’s MSM Drops 5% Solution and LightEyez MSM Eye Drops–Eye Repair due to bacterial contamination, fungal contamination, or both.

The FDA announced a warning this week to consumers about 2 specific eye drop brands for fears of contamination that could cause series eye conditions. The 2 brands in question are: Dr Berne’s MSM Drops 5% Solution and LightEyez MSM Eye Drops.

In the announcement, the FDA wrote it was not aware of any adverse event reports associated with use of either products at that time (August 22). Patients who have signs or symptoms of an eye infection should talk to their health care professional or otherwise seek medical care immediately.

Listed in the table below are the contaminants found in the eye drops:



Dr Berne verbally agreed on August 21, to voluntary recall the Dr. Berne’s MSM Drops 5% Solution. The FDA emailed LightEyez Limited on August 21 to seek to discuss FDA’s concerns with LightEyez products distributed in the US and further steps to protect consumers from using the contaminated eye drops. To date, LightEyez has not responded to FDA or taken action to protect consumers.

When using contaminated eye drops, it can result in minor to serious vision-threatening infection which could possibly progress to a life-threatening infection.

The FDA provided information on how to report adverse events or quality problems with any medicine to FDA’s MedWatch Adverse Event Reporting program:

  • Complete and submit the report online at Medwatch; or
  • Download and complete the form, then submit it via fax at 1-800-FDA-0178.

The federal agency encourages both the general public and providers to report such issues.


Related to this article

Measles Update: November 13, 2026
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.
The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.